Neurogene details new NGN-401 preclinical data, keeps Embolden readout for 2H 2027
Cash of $359.7 million is expected to fund operations into the first quarter of 2029, as PPQ runs remain on track for year-end 2026.
SEC filing (10)
2 stories
Cash of $359.7 million is expected to fund operations into the first quarter of 2029, as PPQ runs remain on track for year-end 2026.
SEC filing (10)
The specialty vaccine company said it will hold a live webcast to discuss results and give a business update.
SEC filing